2019冠状病毒病大流行期间肿瘤坏死因子抑制剂的使用——支持单药治疗的证据 - Suppr

Suppr

超能文献

Use of Tumor Necrosis Factor Inhibitors During the COVID-19 Pandemic-Evidence in Favor of Monotherapy.

作者信息

Velloso Licio A

机构信息

Department of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.

出版信息

JAMA Netw Open. 2021 Oct 1;4(10):e2129707. doi: 10.1001/jamanetworkopen.2021.29707.

DOI:10.1001/jamanetworkopen.2021.29707

PMID:34661668

Abstract

摘要

相似文献

Use of Tumor Necrosis Factor Inhibitors During the COVID-19 Pandemic-Evidence in Favor of Monotherapy.

JAMA Netw Open. 2021 Oct 1;4(10):e2129707. doi: 10.1001/jamanetworkopen.2021.29707.

Therapeutic Decisions in Inflammatory Bowel Disease in the SARS-Cov-2 Pandemic.

Gastroenterology. 2021 Apr;160(5):1883-1884. doi: 10.1053/j.gastro.2020.05.083. Epub 2020 Jun 15.

Anti-TNF Therapy During the SARS-CoV-2 Pandemic: Friend or Foe?

J Crohns Colitis. 2022 May 10;16(4):517-518. doi: 10.1093/ecco-jcc/jjab167.

Should patients stop their biologic treatment during the COVID-19 pandemic.

J Dermatolog Treat. 2020 Jun;31(4):317-318. doi: 10.1080/09546634.2020.1742438. Epub 2020 Mar 19.

Patients with juvenile idiopathic arthritis on TNF inhibitors exposed to COVID-19 family members.

Semin Arthritis Rheum. 2020 Dec;50(6):1214-1215. doi: 10.1016/j.semarthrit.2020.09.012. Epub 2020 Oct 2.

Ambulatory management of perianal Crohn's disease during the COVID-19 pandemic.

Colorectal Dis. 2020 Jun;22(6):645-646. doi: 10.1111/codi.15104. Epub 2020 May 18.

Letter: COVID-19 outcomes and anti-TNF treatments-comprehensive evidence matters.

Aliment Pharmacol Ther. 2022 May;55(9):1233-1234. doi: 10.1111/apt.16872.

[Biological therapy after COVID-19 infection : No reactivation of a COVID-19 infection with positive SARS-CoV-2 antibody status under biological therapy].

Z Rheumatol. 2020 Aug;79(6):574-577. doi: 10.1007/s00393-020-00824-0.

Correspondence on 'Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a patient with COVID-19 with psoriatic arthritis receiving ustekinumab'.

Ann Rheum Dis. 2021 May;80(5):e79. doi: 10.1136/annrheumdis-2020-218029. Epub 2020 Aug 18.

Response to: 'Correspondence on Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a COVID-19 patient with psoriatic arthritis receiving ustekinumab' by Messina .

Ann Rheum Dis. 2021 May;80(5):e80. doi: 10.1136/annrheumdis-2020-218147. Epub 2020 Aug 18.

引用本文的文献

Determination of the factors associated with antigen-specific CD4+ T-cell responses to BNT162b2 in patients with rheumatoid arthritis.

RMD Open. 2024 Jan 12;10(1):e003693. doi: 10.1136/rmdopen-2023-003693.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Use of Tumor Necrosis Factor Inhibitors During the COVID-19 Pandemic-Evidence in Favor of Monotherapy.

JAMA Netw Open. 2021 Oct 1;4(10):e2129707. doi: 10.1001/jamanetworkopen.2021.29707.

Therapeutic Decisions in Inflammatory Bowel Disease in the SARS-Cov-2 Pandemic.

Gastroenterology. 2021 Apr;160(5):1883-1884. doi: 10.1053/j.gastro.2020.05.083. Epub 2020 Jun 15.

Anti-TNF Therapy During the SARS-CoV-2 Pandemic: Friend or Foe?

J Crohns Colitis. 2022 May 10;16(4):517-518. doi: 10.1093/ecco-jcc/jjab167.

Should patients stop their biologic treatment during the COVID-19 pandemic.

J Dermatolog Treat. 2020 Jun;31(4):317-318. doi: 10.1080/09546634.2020.1742438. Epub 2020 Mar 19.

Patients with juvenile idiopathic arthritis on TNF inhibitors exposed to COVID-19 family members.

Semin Arthritis Rheum. 2020 Dec;50(6):1214-1215. doi: 10.1016/j.semarthrit.2020.09.012. Epub 2020 Oct 2.

Ambulatory management of perianal Crohn's disease during the COVID-19 pandemic.

Colorectal Dis. 2020 Jun;22(6):645-646. doi: 10.1111/codi.15104. Epub 2020 May 18.

Letter: COVID-19 outcomes and anti-TNF treatments-comprehensive evidence matters.

Aliment Pharmacol Ther. 2022 May;55(9):1233-1234. doi: 10.1111/apt.16872.

[Biological therapy after COVID-19 infection : No reactivation of a COVID-19 infection with positive SARS-CoV-2 antibody status under biological therapy].

Z Rheumatol. 2020 Aug;79(6):574-577. doi: 10.1007/s00393-020-00824-0.

Ann Rheum Dis. 2021 May;80(5):e79. doi: 10.1136/annrheumdis-2020-218029. Epub 2020 Aug 18.

Ann Rheum Dis. 2021 May;80(5):e80. doi: 10.1136/annrheumdis-2020-218147. Epub 2020 Aug 18.

引用本文的文献

Determination of the factors associated with antigen-specific CD4+ T-cell responses to BNT162b2 in patients with rheumatoid arthritis.

RMD Open. 2024 Jan 12;10(1):e003693. doi: 10.1136/rmdopen-2023-003693.

Use of Tumor Necrosis Factor Inhibitors During the COVID-19 Pandemic-Evidence in Favor of Monotherapy.

作者信息

Velloso Licio A

机构信息

Department of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.

出版信息

JAMA Netw Open. 2021 Oct 1;4(10):e2129707. doi: 10.1001/jamanetworkopen.2021.29707.

DOI:10.1001/jamanetworkopen.2021.29707

PMID:34661668

Abstract

摘要